| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 36.8 | 34.0 | 33.4 |
| Other income | 2.5 | 0.0 | 0.0 |
| Total income | 39.3 | 34.0 | 33.4 |
| Profit before exceptional items & tax | 8.1 | 2.0 | 2.6 |
| Profit before tax | 8.1 | 2.0 | 2.6 |
| Net profit | 3.4 | 0.7 | 2.0 |
| Operating margin | 20.6% | 5.9% | 7.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +70.00% |
|---|---|
| Net profit, quarter on quarter | +385.70% |
| Revenue, year on year | +10.20% |
NSE results filing, NSE: SUNREST. Figures extracted from the filing.
Sunrest Lifescience Ltd: key numbers
- Share price
- ₹37.50
- Market cap
- ₹32.18 Cr
- Revenue (annual)
- ₹70.83 Cr
- Net profit (annual)
- ₹4.12 Cr
- P/E (TTM)
- 7.8×Sector 50.4×
- Promoter holding
- 53.50%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sunrest Lifescience Ltd
All →Sunrest Lifescience Board Meeting Outcome
Sunrest Lifescience Limited has cancelled its Rights Issue due to the non-receipt of the minimum subscription required by SEBI regulations.
Sunrest Lifescience Annual General Meeting
Sunrest Lifescience held its 9th AGM on 7 Sep 2026 via VC/OAVM. Resolutions covered adoption of FY26 financials, re-appointment of MD and WTD, and related-party transaction approval.
Sunrest Lifescience Capital Structure Change
Sunrest Lifescience Limited has extended its ongoing Rights Issue by nine days, with the new closing date set for September 11, 2026.